Page 150 - Read Online

Chen et al. Hepatoma Res 2019;5:12 I http://dx.doi.org/10.20517/2394-5079.2019.03 Page 13 of 17

Copyright
© The Author(s) 2019.

RefeReNCes
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and
mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424.
2. He J, Chen WQ. 2016 Chines Cancer Registry Annual Report. Beijing: Tsinghua Press; 2017. pp. 122-5. (in Chinese)
3. Dong W, Zhang T, Wang ZG, Liu H. Clinical outcome of small hepatocellular carcinoma after different treatments: a meta-analysis.
World J Gastroenterol 2014;20:10174-82.
4. Xu Q, Kobayashi S, Ye X, Meng X. Comparison of hepatic resection and radiofrequency ablation for small hepatocellular carcinoma:
a meta-analysis of 16,103 patients. Sci Rep 2014;4:7252.
5. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011;365:1118-27.
6. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet 2018;391:1301-14.
7. Chen JG, Chen HZ, Zhu J, Yang YL, Zhang YH. Cancer survival in patients from a hospital-based cancer registry, China. J Cancer
2018;9:851-60.
8. El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology
2008;134:1752-63.
9. Zeng HM, Chen WQ, Zheng RS, Zhang SW, Ji JS, et al. Changing cancer survival in China during 2003-15: a pooled analysis of 17
population-based cancer registries. Lancet Glob Health 2018;6:e555-67.
10. Zhou XD, Tang ZY. Management of hepatocellular carcinoma: long-term outcome in 2639 cases. Gan To Kagaku Ryoho 1997;24
Suppl 1:9-16.
11. Zhou XD, Tang ZY, Yu YQ, Yang BH, Lin ZY, et al. Long-term results of surgery for small primary liver cancer in 514 adults. J
Cancer Res Clin Oncol 1996;122:59-62.
12. Chiang CJ, Lo WC, Yang YW, You SL, Chen CJ, et al. Incidence and survival of adult cancer patients in Taiwan, 2002-2012. J Formos
Med Assoc 2016;115:1076-88.
13. Carville KS, MacLachlan JH, Thursfield V, Cowie BC. Hepatocellular carcinoma over three decades in Victoria, Australia:
epidemiology, diagnosis and trends, 1984-2013. Intern Med J 2018;48:835-44.
14. Zhang B, Zhang B, Zhang Z, Huang Z, Chen Y, et al. 42,573 cases of hepatectomy in China: a multicenter retrospective investigation.
Sci China Life Sci 2018;61:660-70.
15. Zhu YR. Clinical implication of AFP serosurvey. Zhonghua Zhong Liu Za Zhi 1983;5:38-40. (in Chinese)
16. Zhu YR, Chen JG, Huang XY. Hepatocellular carcinoma in Qidong County. In: Tang ZY, Wu MC, Xia RS, editors. Primary liver
cancer. China Academic Publisher. Beijing: Springer-Verlag; 1989. pp. 204-22.
17. Abelev GI. Alpha-fetoprotein in ontogenesis and its association with malignant tumors. Adv Cancer Res 1971;14:295-358.
18. Alpert E, Drysdale JW, Isselbacher KJ, Schur PH. Human α-fetoprotein. Isolation, characterization, and demonstration of
microheterogeneity. J Biol Chem 1972;247:3792-8.
19. Chen JG, Parkin DM, Chen QG, Lu JH, Shen QJ, et al. Screening for liver cancer: results of a randomised controlled trial in Qidong,
China. J Med Screen 2003;10:204-9.
20. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol
2004;130:417-22.
21. Bruix J, Sherman M, Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of
hepatocellular carcinoma. Hepatology 2005;42:1208-36.
22. Amarapurkar D, Han KH, Chan HL, Ueno Y, Asia-Pacific Working Party on Prevention of Hepatocellular Carcinoma. Application of
surveillance programs for hepatocellular carcinoma in the Asia-Pacific region. J Gastroenterol Hepatol 2009;24:955-61.
23. Santi V, Trevisani F, Gramenzi A, Grignaschi A, Mirici-Cappa F, et al. Semiannual surveillance is superior to annual surveillance for
the detection of early hepatocellular carcinoma and patient survival. J Hepatol 2010;53:291-7.
24. Tumor Group, Shanghai Institute of Biochemistry, Chinese Academy of Sciences. Progress in A Kind of Fetal Protein. J Biochem
Biophys 1977;9:321-37.
25. Kubota H, Storms RW, Reid LM. Variant forms of alpha-fetoprotein transcripts expressed in human hematopoietic progenitors.
Implications for their developmental potential towards endoderm. J Biol Chem 2002;277:27629-35.
26. Schmelzer E, Zhang L, Bruce A, Wauthier E, Ludlow J, et al. Human hepatic stem cells from fetal and postnatal donors. J Exp Med
2007;204:1973-87.
27. Tatarinov IuS. Some clinical aspects of the study of embryo specific proteins in hepatitis, cirrhosis and primary cancer of the liver.
Vestn Akad Med Nauk SSSR 1970;25:68-73.
28. O’Conor GT, Tatarinov YS, Abelev GI, Uriel J. A collaborative study for the evaluation of a serologic test for primary liver cancer.
Cancer 1970;25:1091-8.
29. Purves LR, van der Merwe E, Bersohn I. Variants of alpha-fetoprotein. Lancet 1970;2:464-5.
30. Tang ZY, Yang BH. Secondary prevention of hepatocellular carcinoma. J Gastroenterol Hepatol 1995;10:683-90.
31. Bretthauer M, Kalager M. Principles, effectiveness and caveats in screening for cancer. Br J Surg 2013;100:55-65.
32. Screening for squamous cervical cancer: duration of low risk after negative results of cervical cytology and its implication
for screening policies. IARC working group on evaluation of cervical cancer screening programmes. Br Med J (Clin Res Ed)
1986;293:659-64.